Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,504,207

« Back to Dashboard

Summary for Patent: 5,504,207

Title: Process and intermediate for the preparation of terazosin hydrochloride dihydrate
Abstract:A process for the preparation of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride (terazosin hydrochloride dihydrate comprises the steps of reacting 4-amino-2-chloro-6,7-dimethoxy-quinazoline with N-(2-tetrahydrofuroyl)piperazine in an anhydrous polar organic solvent in the absence of an added acid scavenger to produce anhydrous 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride (Form IV) and thereafter converting the product of that step to 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-piperazine hydrochloride dihydrate.
Inventor(s): Mannino; Anthony (Round Lake Beach, IL), Henry; Rodger F. (Waukegan, IL), Heitmann; Wayne R. (Lindenhurst, IL), Horrom; Bruce W. (Waukegan, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:08/324,635
Patent Claim Types:
see list of patent claims
Compound; Process;

No matches for this query

International Patent Family for Patent: 5,504,207

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria143959► Subscribe
Brazil1100705► Subscribe
Canada2143971► Subscribe
Germany69500064► Subscribe
Denmark0708104► Subscribe
European Patent Office0708104► Subscribe
Spain2089993► Subscribe
Greece3021319► Subscribe
Greece960300047► Subscribe
Hong Kong130297► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
US Army
Cantor Fitzgerald
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus